The local medical community is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in early trials for addressing obesity. This medication https://auresortwear.com/2026/06/10/retatrutide-australia-my-deep-dive-into-weight-loss-treatments/